FIGURE 8 from DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors
Year: 2023
Type: other
Abstract: Combination of d16 and talazoparib treatment inhibits ovarian cancer growth in vivo. MDAH-2774 cells were subcutaneously implanted into the right flank of NSG mice. Xenografts were randomized into four groups: control (Veh), d16 (20 mg/kg, i.p., twice/week), talazoparib (Tala; 0.5 mg/kg, i.p., once daily, 5 days per week), or combination of d16 and talazoparib (n = 3 in Veh group, n = 4 in the other groups) for 5 weeks. A, Final tumor volume. B, Final tumor weight. C, Mouse body weight. D, Representative IHC images of Ki67 and cleaved PARP1 of xenograft tumor tissues. Quantification is shown in bar graphs. Scale bar, 100 µm. Results are presented as mean ± SD. *, P < 0.05; **, P < 0.01 (two-tailed t test).
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4387673600